Relonova®, new Russian drug for the relief of migraine-associated headaches, is now available in online pharmacies
NovaMedica, together with leading specialists, has developed an Anti-Dementia Program and plans to implement it in medical practice
NovaMedica leaders are in the TOP 1000 Russian managers 2023
NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches.It is manufactured at the capacities of the Technological Center NovaMedica Innotech
NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
NovaMedica registers two own-development CNS products, one without equivalents in Russia and the other – in the world
NovaMedica Launches Own Innovative Drug for the Treatment of Alzheimer’s Disease
NovaMedica signed an agreement with Bayer on transfer of exclusive rights to its product
R&D Center NovaMedica Innotech joined Avifavir production efforts in Russia
The guided tours to the R&D Center NovaMedica Innotech for our most curious and precious visitors – children
Four top managers of NovaMedica make it to the TOP 1000 Russian Managers 2020
NovaMedica will continue working remotely during pundemic
Elena Litvinova appointed new CEO of NovaMedica
NovaMedica and UNIPHARM to localize the production of Melaxen in Russia at the capacities of the R&D Center NovaMedica Innotech
NovaMedica and Pharmsynthez agreed to establish full-cycle manufacturing of several in-demand products in Russia
Five senior managers of NovaMedica were named among the nominees of the Top-1000 Russian Managers rating list for 2018
NovaMedica registered a unique for Russia and rare for the world drug for treatment of proctologic disease
NovaMedica, a portfolio company of RUSNANO, has concluded the biggest SPIC for creation of a greenfield pharmaceutical manufacturing facility in the pharmaceutical industry
NovaMedica R&D Center will become a training facility for implementation of modern pharmaceutical technologies
Interdepartmental Commission has approved NovaMedica’s application for conclusion of SPIC aimed at creation of a new pharmaceutical manufacturing facility
R&D Center of NovaMedica has received GMP-Certificate from the Ministry of Industry and Trade of the Russian Federation
NovaMedica began construction of a pharmaceutical plant in the Kaluga region
NovaMedica appoints Alexander Kuzin as General Director (CEO)
NovaMedica launched Technology Center to develop innovative drugs
NovaMedica and Pfizer won the “Platinum Ounce” award in the nomination “Deal of the Year”
Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines
NovaMedica prepares to launch the new drug development laboratories
Four NovaMedica Executives are in the Top-1000 Russian Managers Rating Released by the Managers Association of Russia and Kommersant Publishing House
Pfizer and NovaMedica announce a strategic partnership in Russia
NovaMedica Strengthens its Team, Elena Ilyina is appointed as Vice President, Business Development.
NovaMedica is starting construction of R&D Center for drug development using nanotechnologies
Cortiment launched in Russia
NovaMedica opens the program of scientific-practical events for Russian gastroenterologists
NovaMedica and Ferring Pharmaceuticals bring innovative gastroenterological products from Switzerland to Russia
NovaMedica Starts its First Media Campaign. It's includes rotation of video commercials produced by BAZELEVS, a movie company owned by a famous director Timur Bekmambetov.
NovaMedica announced plans to create around 15 innovative nanotech-involved pharmaceutical products at the Annual Saint-Petersburg International Economic Forum
Omega Pharma and NovaMedica to market a line of gastrointestinal products under BenegastTM brand in Russia
Horus Pharma and NovaMedica sign agreement to market a portfolio of eye care products in Russia
NovaMedica is recognized one of the best employers of Russia in 2013
SIFI and NovaMedica sign agreement to market eight eye care products in Russia
NovaMedica and Skolkovo Foundation Sign Agreement to Build R&D center
NovaMedica Signs Distribution Agreement with Aptalis Pharma to Develop and Commercialize Gastrointestinal Pharmaceutical Products in Russia
Venter Pharma and NovaMedica Sign Agreement to Commercialize New Lactose Intolerance Test in Russia
Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia
ReVision Optics and NovaMedica sign commercial agreement to market and distribute Raindrop vision correction technology in Russia
NovaMedica, Kaluga Region and City of Kaluga Sign Agreement on Construction of Pharmaceutical Plant
S.Fyodorov Eye Microsurgery Complex and NovaMedica have signed a cooperation agreement on localizing innovative ophthalmic treatment technologies in Russia
Our pipeline has recently been complemented by the addition of three new products Marinus Pharmaceuticals, Lithera and Regado Biosciences, all of which are developers of advanced pharmaceutical solutions.
The production site of the NovaMedica will be chosen in the 1st quarter of 2013
NovaMedica announces the opening of its US office
Fabrice Egros was appointed as COO, Pharmaceutical Director and board member of NovaMedica a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates.
Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive network of venture investors in the sector here in Russia.
Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets.
Signing of the agreement between RUSNANO, Domain Associates LLC and Team Drive on the management and operation of the NovaMedica investment program.
RUSNANO and Domain Associates LLC announced the launch of their joint investment program.
26 December 2023
09 November 2023
09 November 2023
29 February 2024
29 February 2024
28 February 2024
28 February 2024